The MET Oncogene as a Therapeutical Target in Cancer Invasive Growth

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• The MET proto-oncogene encodes a tyrosine kinase receptor for Hepatocyte Growth Factor (HGF).
• MET signaling regulates invasive growth, a process involving cell proliferation, extracellular matrix invasion, and apoptosis resistance.
• Physiological roles include embryonic development, wound healing, and tissue regeneration.

Purpose of the Study:

• To investigate the role of MET proto-oncogene in pathological invasive growth and metastasis.
• To explore MET as a therapeutic target for cancer treatment.
• To understand the interplay between MET and the protease network for effective inhibition strategies.

Main Methods:

• Analysis of MET proto-oncogene expression and mutations in tumors.
• Investigating small molecule kinase inhibitors targeting MET.
• Developing inhibitory antibodies against MET and its ligand HGF.
• Studying the interaction of MET with the protease network.

Main Results:

• MET overexpression and/or mutations are associated with pathological invasive growth and metastasis in various tumors.
• MET signaling sustains tumor progression and is a critical factor in metastasis.
• Targeting MET with kinase inhibitors or antibodies shows promise for cancer therapy.
• Exploiting the interplay between MET and proteases offers new avenues for therapeutic intervention.

Conclusions:

• The MET proto-oncogene is a critical regulator of invasive growth, with dysregulation driving cancer metastasis.
• Targeting MET and its signaling pathway presents a promising strategy for developing novel anti-cancer therapies.
• Understanding the MET-protease network interactions is key to achieving effective inhibition of pathological invasive growth.